ECM Medical is an international medical diagnostic device company based in Hong Kong, China and the US, with offices in Shanghai, Shenzhen, Minneapolis and San Francisco. The senior management of the company is a mix of American and Chinese executives with decades of experience at medical device, life science, and investment companies in both China and the United States.
ECM Medical partners with international healthcare firms to bring the best diagnostic products to market and works to ensure the products have the best access to Asia and Australasia.
ECM licenses products approved in their home countries and then performs and funds the steps necessary to achieve China FDA approval before marketing and selling those products across China. ECM Medical provides western medical device companies with an additional revenue stream without the investment and management distractions normally associated with selling medical device products in the China markets.
ECM Medical also has a consumer products division that follows the same method of licensing products from western companies and distributing them in China, Hong Kong and Macau.
BRIAN HAKIM – VP, USA
Brian Hakim has more than 20 years of experience in medical device development, marketing and pipeline strategy, primarily in the cardiovascular, orthopedic and drug delivery areas. Brian served in several pipeline and marketing roles at Medtronic, as Director of Marketing at Velomedix and as a cofounder at BioCardia, where he helped design Biocardia’s initial drug delivery catheter products. Earlier, Brian had lead engineering roles at both IsoStent and Baxter Healthcare. He has three patents and received an MS in Mechanical Engineering from the University of Minnesota and an MBA from the Kellogg School of Management.
JONATHAN HAKIM – VP MARKETING
Jonathan Hakim has 20 years of experience in Greater China with a focus on healthcare, IT and Venture Capital. Jonathan co-founded various internet companies including Boom Securities (Now Monex Boom Securities), TP Labs (Division of Crosby Capital (8088)), I and I Asia and Gorilla Asia before moving into healthcare. Jonathan worked with Synovate Healthcare, Ogilvy’s Healthcare Division and Berlin Chemie prior to building the international business for Beike Biotech. Jonathan has a BA in Economics and Computer Science from Northwestern University in Chicago.
Dr. Kyle is a Professor of Orthopedic Surgery at the University of Minnesota, the Past President of the American Academy of Orthopedic Surgeons, a Co-Founder and Past President of the Orthopedic Trauma Association and the Medical Director of Excelen Center for Bone & Joint Research and Education. Dr. Kyle holds sixteen patents on developments for orthopedic implants. He has worked extensively with major orthopedic companies including DePuy, Smith & Nephew, Zimmer, Biomet, and DJO on the designs for total hip and knee implants. He was one of the first surgeons to help design and use titanium orthopedic implants in the world. Among his designs are innovations in bone ingrowth, femoral and acetabular prosthesis for the hip, a total knee replacement system, cannulated screws with unique self tapping capabilities, multiple plates and screws for fixing fractures above joints, and intramedullary locking nails to fit long bone fractures.
Zhou Xin has fourteen years of experience in the medical device industry in China with a primary focus on orthopedics. He was with J&J for 9 years in various sales roles for DePuy and Synthes. He then became the Vice General Manager for MicroPort Medical and responsible for sales for both Shanghai MicroPort Orthopedics and Suzhou Health Medical companies before becoming the General Manager for Bonovo Orthopedics and leading both commercial and manufacturing operations of the company.
Having studied and worked for more than 10 years in Sweden and Canada, Dr. Hu returned to China to focus on developing stem cell research. In July 2005, Dr. Hu founded Shenzhen Beike Biotechnology Co. Ltd. creating a platform for the advanced research of stem cell technology. For his outstanding achievements in the field of adult stem cell research and its clinical translation, Dr. Hu was listed in the “Thousand Talents Program (the Recruitment Program of Global Experts)” by the CPC Central Committee in 2008. Since September 2010, Dr. Xiang Hu has served as the Member of Standing Committee of the Regenerative Medicine Committee of the China Medical Biotech Association. He is also the Vice Director General of the National Technology Innovation Strategic Alliance of Stem Cell and Regenerative Medicine. Dr. Hu received his PhD in Biochemistry and Molecular Biology from the University of Gothenburg and Chalmers University of Technology (Sweden), and conducted post-doctoral research at the University of British Columbia (Canada).
Serafin has served as a Venture Partner for Affinity Capital, gaining over 12 years of healthcare venture capital experience through three VC fund cycles. Prior to Affinity, Fin served 12 years in the medical device industry with VC-backed orthopedic and spine device start-up companies where he led new product development projects from concept to commercialization including Orthomet and Spine-Tech. Fin has a BS in Biomedical Engineering from The Catholic University of America, a dual Masters in Biomedical Engineering and Mechanical Engineering from the University of Michigan and an MBA from the University of Minnesota, Carlson School of Management.